MGUS is a dubious disease in the field of blood tumors, clinical manifestations are complex and often involve multi-system complications. Early identification and standardized clinical treatment are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical manifestations, imaging inspections, laboratory tests and pathological biopsies.
The platform can help to align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management programs for MGUS require individualized development, typically including drug treatment, rehabilitation periodic interventions, and follow-up to multidimensional management programs. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, with timely adjustments according to the changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of the MGUS for unambiguous clonal squamous cell disease. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.